Advertisement

Tumor Biology

, Volume 36, Issue 7, pp 4961–4966 | Cite as

Trends in gynaecological cancers in the largest obstetrics and gynaecology hospital in China from 2003 to 2013

  • XueLian Li
  • SaiHua Zheng
  • ShangJie Chen
  • Feng Qin
  • Sandy Lau
  • Qi Chen
Research Article

Abstract

The incidence and the trend of gynaecological cancers have been suggested to vary by ethnicity and geographical regions. Whether the incidence and type of gynaecological cancers in China is different have not been fully investigated. In this study, we reported the trend of gynaecological cancers in China. Data on 13,518 women with gynaecological cancers were collected from the largest obstetrics and gynaecology hospital in China from 2003 to 2013. Data included age at diagnosis and the annual number of women with diagnosed endometrial, ovarian, cervical cancer and other gynaecological cancers. The number of women with diagnosed gynaecological cancers increased by almost sixfold in 2013 compared to that in 2003. It was largely due to the increase of women with newly diagnosed cervical cancer. The percentage of women with endometrial and ovarian cancer within total gynaecological cancers was decreased, whilst the percentage of cervical cancer significantly increased between 2003 and 2013. The mean age of women with endometrial or ovarian cancer at diagnosis was 53 or 48 years, respectively, which was no difference over 11 years. However, the mean age of women with cervical cancer at diagnosis was significantly delayed from 42 years in 2003 to 46 years since 2011. This was also confirmed by the age-specific distribution of gynaecological cancers over 11 years. Our study found that the age onset of endometrial and ovarian cancer has not changed over 11 years. But the age onset of cervical cancer is delayed since 2011 in China.

Keywords

Gynaecological cancer Endometrial cancer Ovarian cancer Cervical cancer Age at diagnosis China 

Notes

Acknowledgments

This study was supported by Shanghai Hospitals Association Foundation (grant number 2014052 to Xuelian Li). We would like to thank Dr. Greg Gamble from the University of Auckland for statistical analysis help.

Conflict of interest

None

Supplementary material

13277_2015_3143_MOESM1_ESM.doc (97 kb)
Figure 1 The age-specific distribution of endometrial cancer based on the number (A) or percentage (B) between 2003 and 2013. (DOC 97 kb)
13277_2015_3143_MOESM2_ESM.doc (94 kb)
Figure 2 The age-specific distribution of ovarian cancer based on the number (A) or percentage (B) between 2003 and 2013. (DOC 94 kb)
13277_2015_3143_MOESM3_ESM.doc (89 kb)
Figure 3 The age-specific distribution of cervical cancer based on the number (A) or percentage (B) between 2003 and 2013 (DOC 89 kb)
13277_2015_3143_MOESM4_ESM.doc (34 kb)
Table 1 Age-specific distribution of endometrial cancer, ovarian cancer and cervical cancer during study period (DOC 34 kb)

References

  1. 1.
    Standards of service provision for gynaecological cancer patients in New Zealand - Provisional., M.o. Health, Editor. National Gynaecological Cancer Tumour Standards Working Group: Wellington; 2013.Google Scholar
  2. 2.
    Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, et al. National Endometrial Cancer Study, age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012;176(4):269–78.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Olson SH, Atoria CL, Cote ML, Cook LS, Rastogi R, Soslow RA, et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(5):753–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 2013;22(2):233–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Cook LS, Kmet LM, Magliocco AM, Weiss NS. Endometrial cancer survival among U.S. black and white women by birth cohort. Epidemiology. 2006;17(4):469–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407.CrossRefPubMedGoogle Scholar
  7. 7.
    Cook LS WN, Doherty JA, Chen C. Endometrial cancer: cancer epidemiology and prevention. New York: Oxford University Press; 2006.CrossRefGoogle Scholar
  8. 8.
    Howlader N, NA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. 2014.Google Scholar
  9. 9.
    Kent A. HPV vaccination and testing. Rev Obstet Gynecol. 2010;3(1):33–4.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev. 2014;5:CD010681.Google Scholar
  11. 11.
    Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16(3):217–30.PubMedGoogle Scholar
  12. 12.
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study. Lancet. 2012;380(9859):2095–128.CrossRefPubMedGoogle Scholar
  13. 13.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMedGoogle Scholar
  14. 14.
    Gynaecological cancers in Australia: an overview: Australian Institute of Health and Welfare & Cancer Australia. 2012.Google Scholar
  15. 15.
    Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Lentz GM, L.R., Gershenson DM, Katz VL. Comprehensive gynecology 6th ed. Neoplastic diseases of the uterus: Mosby. 2013Google Scholar
  17. 17.
    Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):vi33–8.PubMedGoogle Scholar
  18. 18.
    Yang D, Haines CJ, Pan P, Zhang Q, Sun Y, Hong S, et al. Menopausal symptoms in mid-life women in southern China. Climacteric. 2008;11(4):329–36.CrossRefPubMedGoogle Scholar
  19. 19.
    Mahdi H, Schlick CJ, Kowk LL, Moslemi-Kebria M, Michener C. Endometrial cancer in Asian and American Indian/Alaskan native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women. Gynecol Oncol. 2014;132(2):443–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Ries LAG, YJ, Keel GE, Eisner MP, Lin YD. Horner M-J SEER Survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute. Chapter 16: Cancers of the Ovary. 2007.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • XueLian Li
    • 1
    • 2
  • SaiHua Zheng
    • 1
  • ShangJie Chen
    • 1
  • Feng Qin
    • 1
  • Sandy Lau
    • 3
  • Qi Chen
    • 1
    • 4
  1. 1.The Hospital of Obstetrics and GynaecologyFudan UniversityShanghaiChina
  2. 2.Shanghai Key Laboratory of Female Reproductive Endocrine Related DiseasesShanghaiChina
  3. 3.Auckland Bioengineering InstituteThe University of AucklandAucklandNew Zealand
  4. 4.Department of Obstetrics and GynaecologyThe University of AucklandAucklandNew Zealand

Personalised recommendations